Network pharmacology and experimental verification-based strategy for exploring the mechanisms of luteolin in the treatment of osteosarcoma.

Background: Luteolin is an active ingredient in various traditional Chinese medicines for the treatment of multiple tumors. However, the mechanisms of its inhibitory effect on osteosarcoma proliferation and metastasis remain unclear.

Purpose: To elucidate the anti-osteosarcoma mechanisms of luteolin based on network pharmacology and experimental verification.

Super-enhancer-driven MLX mediates redox balance maintenance via SLC7A11 in osteosarcoma.

Osteosarcoma (OS) is a common type of bone tumor for which there has been limited therapeutic progress over the past three decades. The prevalence of transcriptional addiction in cancer cells emphasizes the biological significance and clinical relevance of super-enhancers. In this study, we found that Max-like protein X (MLX), a member of the Myc-MLX network, is driven by super-enhancers.

Named entity recognition for Chinese based on global pointer and adversarial training.

Named entity recognition aims to identify entities from unstructured text and is an important subtask for natural language processing and building knowledge graphs. Most of the existing entity recognition methods use conditional random fields as label decoders or use pointer networks for entity recognition. However, when the number of tags is large, the computational cost of method based on conditional random fields is high and the problem of nested entities cannot be solved.

Single-cell transcriptome analysis reveals T-cell exhaustion in denosumab-treated giant cell tumor of bone.

Denosumab (DMAB), a human monoclonal antibody against the receptor activator of the nuclear factor-kappa B ligand, is used for the treatment for unresectable giant cell tumor of bone (GCTB). However, little is known about the molecular and functional characteristics of GCTB-infiltrating lymphocytes after DMAB treatment. Here, we performed single-cell RNA sequencing and immunostaining assays to delineate the immune landscape of GCTB in the presence and absence of DMAB.